

**PB 80 of 2023**

**National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023
(No. 7)**

*National Health Act 1953*

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 30 August 2023

**NIKOLAI TSYGANOV**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015). 2

1 Name

1. This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 7)*.
2. This instrument may also be cited as PB 80 of 2023.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 September 2023* | *1 September 2023* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)*

1. Schedule 1, after entry for Adalimumab in the form Injection 80 mg in 0.8 mL pre-filled syringe *[Maximum Quantity: 3; Number of
Repeats: 0]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Adapalene with benzoyl peroxide | Gel 1 mg-25 mg per g, 30 g | 20 | 2 | 3 |  |

1. Schedule 1, entry for Alendronic acid

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Alendronic acid | Tablet 70 mg (as alendronate sodium) | 20 | 4 | 5 |  |
|  |  | 20 | 8 | 5 |  |

1. Schedule 1, entry for Allopurinol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Allopurinol | Tablet 100 mg | 20 | 200 | 2 |  |
|  |  | 20 | 400 | 2 |  |
|  | Tablet 300 mg | 20 | 60 | 2 |  |
|  |  | 20 | 120 | 2 |  |

1. Schedule 1, entry for Amlodipine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Amlodipine | Tablet 5 mg (as besilate) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg (as besilate) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Amlodipine with atorvastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Amlodipine with atorvastatin | Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |

1. Schedule 1, entry for Amlodipine with valsartan

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Amlodipine with valsartan | Tablet 5 mg (as besilate)‑80 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 5 mg (as besilate)‑160 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 5 mg (as besilate)‑320 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑320 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Amlodipine with valsartan and hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Amlodipine with valsartan and hydrochlorothiazide | Tablet 5 mg (as besilate)‑160 mg‑12.5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 5 mg (as besilate)‑160 mg‑25 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg‑12.5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg‑25 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑320 mg‑25 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Apixaban

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Apixaban | Tablet 2.5 mg | 20 | 60 | 0 |  |
|  |  | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |
|  | Tablet 5 mg | 20 | 28 | 0 |  |
|  |  | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |

1. Schedule 1, entry for Atenolol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 5 |  |
|  | Tablet 50 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Atorvastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 10 mg (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 20 mg (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 40 mg (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 80 mg (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, after entry for Auranofin in the form Tablet 3 mg

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Azacitidine | Tablet 200 mg | 20 | 14 | 2 |  |
|  | Tablet 300 mg | 20 | 14 | 2 |  |
|  |  | 20 | 21 | 1 |  |

1. Schedule 1, entry for Baclofen

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Baclofen | Tablet 10 mg | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet 25 mg | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |

1. Schedule 1, entry for Balsalazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Balsalazide | Capsule containing balsalazide sodium 750 mg | 20 | 280 | 5 |  |
|  |  | 20 | 560 | 5 |  |

1. Schedule 1, entry for Bisoprolol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet containing bisoprolol fumarate 5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet containing bisoprolol fumarate 10 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, after entry for Cabozantinib in the form Tablet 60 mg *[Maximum Quantity: 30; Number of Repeats: 5]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Calcipotriol with betamethasone | Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g | 20 | 2 | 1 |  |
|  | Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g | 20 | 2 | 1 |  |

1. Schedule 1, entry for Calcitriol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Calcitriol | Capsule 0.25 microgram | 20 | 100 | 3 |  |
|  |  | 20 | 200 | 3 |  |

1. Schedule 1, entry for Calcium

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | 20 | 480 | 1 |  |
|  | Tablet 600 mg (as carbonate) | 20 | 240 | 1 |  |
|  |  | 20 | 480 | 1 |  |

1. Schedule 1, entry for Candesartan

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 8 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 16 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Candesartan with hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Carvedilol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Carvedilol | Tablet 6.25 mg | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |
|  | Tablet 12.5 mg | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |
|  | Tablet 25 mg | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |

1. Schedule 1, after entry for Certolizumab pegol in the form Solution for injection 200 mg in 1 mL pre-filled pen

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Chlortalidone | Tablet 25 mg | 20 | 200 | 1 |  |

1. Schedule 1, entry for Clonidine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Clonidine | Tablet containing clonidine hydrochloride 100 micrograms | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet containing clonidine hydrochloride 150 micrograms | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |

1. Schedule 1, entry for Clopidogrel

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Clopidogrel | Tablet 75 mg (as besilate) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 75 mg (as hydrogen sulfate) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Clopidogrel with aspirin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Dabigatran etexilate

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Dabigatran etexilate | Capsule 75 mg (as mesilate) | 20 | 60 | 0 |  |
|  | Capsule 110 mg (as mesilate) | 20 | 60 | 0 |  |
|  |  | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |
|  | Capsule 150 mg (as mesilate) | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |

1. Schedule 1, entry for Enalapril

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing enalapril maleate 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing enalapril maleate 20 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Enalapril with hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Enalapril with hydrochlorothiazide | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Eplerenone

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Eplerenone | Tablet 25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 50 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Ezetimibe

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ezetimibe | Tablet 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Ezetimibe and rosuvastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 5 |  |

1. Schedule 1, entry for Ezetimibe with atorvastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ezetimibe with atorvastatin | Tablet 10 mg‑10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg‑20 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg‑40 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg‑80 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Ezetimibe with simvastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg‑20 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg‑40 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg‑80 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Febuxostat

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Febuxostat | Tablet 80 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Felodipine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Felodipine | Tablet 2.5 mg (extended release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 5 mg (extended release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg (extended release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Fenofibrate

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Fenofibrate | Tablet 48 mg | 20 | 60 | 5 |  |
|  |  | 20 | 60 | 11 |  |
|  |  | 20 | 120 | 5 |  |
|  | Tablet 145 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Fluvastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Fluvastatin | Tablet (prolonged release) 80 mg (as sodium) | 20 | 28 | 5 |  |
|  |  | 20 | 28 | 11 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Furosemide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Furosemide | Oral solution 10 mg per mL, 30 mL | 20 | 2 | 3 |  |
|  | Tablet 20 mg | 20 | 100 | 1 |  |
|  |  | 20 | 200 | 1 |  |
|  | Tablet 40 mg | 20 | 100 | 1 |  |
|  |  | 20 | 200 | 1 |  |
|  | Tablet 500 mg | 20 | 100 | 3 |  |

1. Schedule 1, entry for Gemfibrozil

*substitute:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gemfibrozil | Tablet 600 mg | 20 | 60 | 5 |
|  |  | 20 | 60 | 11 |
|  |  | 20 | 120 | 5 |

1. Schedule 1, entry for Glyceryl trinitrate

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | 20 | 2 | 5 |  |
|  | Transdermal patch 18 mg | 20 | 30 | 5 |  |
|  | Transdermal patch 25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Transdermal patch 36 mg | 20 | 30 | 5 |  |
|  | Transdermal patch 50 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Transdermal patch 54 mg | 20 | 30 | 5 |  |

1. Schedule 1, entry for Hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Hydrochlorothiazide | Tablet 25 mg | 20 | 100 | 1 |  |
|  |  | 20 | 200 | 1 |  |

1. Schedule 1, entry for Hydrochlorothiazide with amiloride

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Hydrochlorothiazide with amiloride | Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg | 20 | 100 | 1 |  |
|  |  | 20 | 200 | 1 |  |

1. Schedule 1, entry for Indapamide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Indapamide | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | 20 | 90 | 1 |  |
|  |  | 20 | 180 | 1 |  |
|  | Tablet containing indapamide hemihydrate 2.5 mg | 20 | 90 | 1 |  |
|  |  | 20 | 180 | 1 |  |

1. Schedule 1, entry for Irbesartan

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Irbesartan | Tablet 75 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 150 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 300 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Irbesartan with hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg‑12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 300 mg‑12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 300 mg‑25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, after entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg *[Maximum Quantity: 60; Number of Repeats: 5]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Isosorbide dinitrate | Tablet 5 mg (sublingual) | 20 | 400 | 2 |  |

1. Schedule 1, entry for Isosorbide mononitrate

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Isosorbide mononitrate | Tablet 60 mg (sustained release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 120 mg (sustained release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Lercanidipine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet containing lercanidipine hydrochloride 20 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Lercanidipine with enalapril

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Lercanidipine with enalapril | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Lisinopril

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Lisinopril | Tablet 5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 20 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, omit entry for Losartan
2. Schedule 1, entry for Mesalazine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Mesalazine | Sachet containing granules, 500 mg per sachet | 20 | 200 | 5 |  |
|  |  | 20 | 400 | 5 |  |
|  | Sachet containing granules, 1 g per sachet | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Sachet containing granules, 1.5 g per sachet | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |
|  | Sachet containing granules, 3 g per sachet | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Sachet containing prolonged release granules, 1 g per sachet | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Sachet containing prolonged release granules, 2 g per sachet | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |
|  | Sachet containing prolonged release granules, 4 g per sachet | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 250 mg (enteric coated) | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet 500 mg (enteric coated) | 20 | 200 | 5 |  |
|  |  | 20 | 400 | 5 |  |
|  | Tablet 500 mg (prolonged release) | 20 | 200 | 5 |  |
|  |  | 20 | 400 | 5 |  |
|  | Tablet 800 mg (enteric coated) | 20 | 90 | 5 |  |
|  |  | 20 | 180 | 5 |  |
|  | Tablet 1 g (enteric coated) | 20 | 120 | 5 |  |
|  |  | 20 | 240 | 5 |  |
|  | Tablet 1 g (prolonged release) | 20 | 120 | 5 |  |
|  |  | 20 | 240 | 5 |  |
|  | Tablet 1.2 g (prolonged release) | 20 | 120 | 5 |  |
|  |  | 20 | 240 | 5 |  |
|  | Tablet 1.6 g (enteric coated) | 20 | 120 | 4 |  |
|  |  | 20 | 240 | 4 |  |

1. Schedule 1, entry for Metoprolol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet containing metoprolol tartrate 100 mg | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |

1. Schedule 1, entry for Metoprolol succinate

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Metoprolol succinate | Tablet 47.5 mg (controlled release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 95 mg (controlled release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 190 mg (controlled release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Moxonidine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Moxonidine | Tablet 200 micrograms | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 400 micrograms | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Nebivolol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Nebivolol | Tablet 1.25 mg (as hydrochloride) | 20 | 56 | 5 |  |
|  |  | 20 | 112 | 5 |  |
|  | Tablet 5 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 10 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Nicorandil

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Nicorandil | Tablets 10 mg, 60 | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 5 |  |
|  | Tablets 20 mg, 60 | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 5 |  |

1. Schedule 1, entry for Nifedipine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Nifedipine | Tablet 30 mg (controlled release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 60 mg (controlled release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, omit entry for Norethisterone with mestranol
2. Schedule 1, entry for Olmesartan

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Olmesartan with amlodipine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | 20 | 30 | 5 |  |

1. Schedule 1, entry for Olmesartan with amlodipine and hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | 20 | 30 | 5 |  |

1. Schedule 1, entry for Olmesartan with hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Ozanimod

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ozanimod | Capsule 920 micrograms | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 5 |  |
|  | Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms | 20 | 1 | 0 |  |

1. Schedule 1, after entry for Palbociclib in the form Tablet 125 mg

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Pancreatic extract | Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity | 20 | 1000 | 10 |  |
|  | Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity | 20 | 400 | 10 |  |
|  | Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity | 20 | 400 | 10 |  |
|  | Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g | 20 | 6 | 10 |  |

1. Schedule 1, after entry for Paroxetine

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Patiromer | Powder for oral suspension 8.4 g | 20 | 30 | 5 |  |
|  | Powder for oral suspension 16.8 g | 20 | 30 | 5 |  |

1. Schedule 1, after entry for Pazopanib in the form Tablet 400 mg (as hydrochloride) *[Maximum Quantity: 60; Number of Repeats: 5]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Penicillamine | Tablet 125 mg | 20 | 200 | 1 |  |
|  | Tablet 250 mg | 20 | 200 | 1 |  |

1. Schedule 1, entry for Perindopril

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril arginine 2.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing perindopril arginine 5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing perindopril arginine 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing perindopril erbumine 2 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing perindopril erbumine 4 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing perindopril erbumine 8 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Perindopril with amlodipine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Perindopril with indapamide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Perindopril with indapamide | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Potassium chloride

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Potassium chloride | Tablet 600 mg (sustained release) | 20 | 200 | 1 |  |
|  |  | 20 | 400 | 1 |  |

1. Schedule 1, entry for Potassium chloride with potassium bicarbonate

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Potassium chloride with potassium bicarbonate | Tablet, effervescent, 14 mmol potassium and 8 mmol chloride | 20 | 60 | 1 |  |
|  |  | 20 | 120 | 1 |  |

1. Schedule 1, entry for Pravastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Pravastatin | Tablet containing pravastatin sodium 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing pravastatin sodium 20 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing pravastatin sodium 40 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing pravastatin sodium 80 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Prazosin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Prazosin | Tablet 1 mg (as hydrochloride) | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet 2 mg (as hydrochloride) | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet 5 mg (as hydrochloride) | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |

1. Schedule 1, entry for Propranolol

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Propranolol | Tablet containing propranolol hydrochloride 10 mg | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet containing propranolol hydrochloride 40 mg | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |

1. Schedule 1, entry for Raloxifene

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Ramipril

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ramipril | Capsule 1.25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Capsule 2.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Capsule 5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Capsule 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 1.25 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 2.5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Ramipril with felodipine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 5 mg‑5 mg (modified release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Risedronic acid

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Risedronic acid | Tablet containing risedronate sodium 5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet containing risedronate sodium 30 mg | 20 | 28 | 1 |  |
|  | Tablet containing risedronate sodium 35 mg | 20 | 4 | 5 |  |
|  |  | 20 | 8 | 5 |  |
|  | Tablet containing risedronate sodium 150 mg | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 5 |  |
|  | Tablet (enteric coated) containing risedronate sodium 35 mg | 20 | 4 | 5 |  |
|  |  | 20 | 8 | 5 |  |

1. Schedule 1, entry for Rivaroxaban

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Rivaroxaban | Tablet 2.5 mg | 20 | 60 | 5 |  |
|  |  | 20 | 120 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 15 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 20 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Rosuvastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Rosuvastatin | Tablet 5 mg (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 20 mg (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 40 mg (as calcium) | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Sacubitril with valsartan

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Sacubitril with valsartan | Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg | 20 | 56 | 5 |  |
|  |  | 20 | 112 | 5 |  |
|  | Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg | 20 | 56 | 5 |  |
|  |  | 20 | 112 | 5 |  |
|  | Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg | 20 | 56 | 5 |  |
|  |  | 20 | 112 | 5 |  |

1. Schedule 1, entry for Simvastatin

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Simvastatin | Tablet 5 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 20 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 40 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 80 mg | 20 | 30 | 5 |  |
|  |  | 20 | 30 | 11 |  |
|  |  | 20 | 60 | 5 |  |

1. Schedule 1, entry for Spironolactone

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Spironolactone | Tablet 25 mg | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet 100 mg | 20 | 100 | 5 |  |

1. Schedule 1, entry for Sulfasalazine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Sulfasalazine | Tablet 500 mg | 20 | 200 | 5 |  |
|  |  | 20 | 200 | 11 |  |
|  |  | 20 | 400 | 5 |  |
|  | Tablet 500 mg (enteric coated) | 20 | 200 | 5 |  |
|  |  | 20 | 200 | 11 |  |
|  |  | 20 | 400 | 5 |  |

1. Schedule 1, entry for Telmisartan

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Telmisartan | Tablet 40 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 80 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Telmisartan with amlodipine

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Telmisartan with amlodipine | Tablet 40 mg‑5 mg (as besilate) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 40 mg‑10 mg (as besilate) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 80 mg‑5 mg (as besilate) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 80 mg‑10 mg (as besilate) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Telmisartan with hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Telmisartan with hydrochlorothiazide | Tablet 40 mg‑12.5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 80 mg‑12.5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 80 mg‑25 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, after entry for Theophylline in the form Tablet 300 mg (sustained release)

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | 20 | 200 | 2 |  |

1. Schedule 1, entry for Ticagrelor

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ticagrelor | Tablet 90 mg | 20 | 56 | 5 |  |
|  |  | 20 | 112 | 5 |  |

1. Schedule 1, entry for Trandolapril

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Trandolapril | Capsule 500 micrograms | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Capsule 1 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Capsule 2 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Capsule 4 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Trandolapril with verapamil

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Trandolapril with verapamil | Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Valsartan

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Valsartan | Tablet 80 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 160 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 320 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Valsartan with hydrochlorothiazide

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Valsartan with hydrochlorothiazide | Tablet 80 mg‑12.5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 160 mg‑12.5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 160 mg‑25 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 320 mg‑12.5 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 320 mg‑25 mg | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |

1. Schedule 1, entry for Verapamil

*substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Verapamil | Tablet containing verapamil hydrochloride 80 mg | 20 | 100 | 5 |  |
|  |  | 20 | 200 | 5 |  |
|  | Tablet containing verapamil hydrochloride 180 mg (sustained release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet containing verapamil hydrochloride 240 mg (sustained release) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |